World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
117
Citations
60675
World Ranking
4161
National Ranking
405

Overview

Ian Judson is affiliated with the Institute of Cancer Research in the United Kingdom. Their academic contributions focus primarily on the field of Medicine, with a strong concentration in Oncology and related subfields such as Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Surgery, and Gastroenterology.

The scientist's research topics span across several areas, notably Sarcoma Diagnosis and Treatment, Vascular Tumors and Angiosarcomas, Gastrointestinal Tumor Research and Treatment, Cardiac Tumors and Thrombi, Uterine Myomas and Treatments, as well as Lymphoma Diagnosis and Treatment, and broader Gastrointestinal Disorders and Treatments.

Ian Judson has published multiple papers in renowned scientific journals. Recent publications include:

  • The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients, 2020, European Journal of Cancer
  • Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, 2020, Annals of Oncology
  • Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib, 2020, JAMA Surgery
  • UK guidelines for the management of soft tissue sarcomas, 2024, British Journal of Cancer
  • Carboplatin dosage: prospective evaluation of a simple formula based on renal function, 2023, Journal of Clinical Oncology

Frequent co-authors collaborating with Ian Judson include:

  • Robin L. Jones
  • Hans Gelderblom
  • Winette T.A. van der Graaf
  • Sandrine Marréaud
  • Saskia Litière

Ian Judson's publications appear regularly in several key scientific venues such as:

  • European Journal of Cancer
  • Annals of Oncology
  • British Journal of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • JAMA Surgery

Their work reflects involvement in interdisciplinary research that intersects clinical guidelines, surgery outcomes, and cancer treatment protocols. The recurring appearance of sarcoma diagnosis and treatment as a focus area suggests a specialization in soft tissue and vascular tumor research.

Best Publications

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

    A H Calvert;D R Newell;L A Gumbrell;S O'Reilly

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

    Allan T van Oosterom;Ian Judson;Jaap Verweij;Sigrid Stroobants

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Soft-Tissue Sarcomas in Adults

    Matthew A Clark;Cyril Fisher;Ian Judson;J Meirion Thomas

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

    Nathalie Gaspar;Douglas S. Hawkins;Uta Dirksen;Ian J. Lewis

  • Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

    Josep Tabernero;Federico Rojo;Emiliano Calvo;Howard Burris

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Malignant Gastrointestinal Stromal Tumor: Distribution, Imaging Features, and Pattern of Metastatic Spread

    Guy J. C. Burkill;Mohammed Badran;Omar Al-Muderis;J. Meirion Thomas

  • Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

    Udai Banerji;Anne O'Donnell;Michelle Scurr;Simon Pacey

  • ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of L1210 Tumor Cell Growth in Vitro and in Vivo: A New Agent for Clinical Study

    Jackman Al;Taylor Ga;Gibson W;Kimbell R

Frequent Co-Authors

Cyril Fisher
Cyril Fisher Royal Marsden NHS Foundation Trust
Paolo G. Casali
Paolo G. Casali University of Milan
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Martin O. Leach
Martin O. Leach Royal Marsden NHS Foundation Trust
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Alessandro Gronchi
Alessandro Gronchi University of Milan
Peter Hohenberger
Peter Hohenberger Heidelberg University
Florence I. Raynaud
Florence I. Raynaud Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering alternative or complementary paths to a traditional MD program, there are excellent online options to explore. For those interested in advanced nursing without prior nursing experience, direct entry msn online programs offer a fast-track to a Master’s in Nursing, designed specifically for non-nurses.

If your goal is to earn a bachelor's degree in nursing more flexibly, online bsn programs for non nurses provide accessible routes, even if you don’t have previous nursing credentials. These programs are ideal for career changers looking to quickly enter the healthcare workforce.

Not all healthcare careers require direct patient care. Administrative roles such as medical billing and coding are in high demand, and many reputable programs are available fully online. For those concerned about costs, searching for financial aid for medical billing and coding can make these programs much more affordable.

Additionally, some nursing schools are removing standardized test barriers. Explore nursing schools that don't require teas or hesi to discover programs with simplified admissions. These degree and certification pathways offer flexible alternatives tailored to diverse educational backgrounds and career interests.

Best Scientists Citing Ian Judson

Trending Scientists